Evidence map›Paper›PMID 35633182›Full record

ArticleCancer science2022

Estrogen induces the expression of EBV lytic protein ZEBRA, a marker of poor prognosis in nasopharyngeal carcinoma.

Hirotomo Dochi, Satoru Kondo, Takayuki Murata, Masaki Fukuyo, Asuka Nanbo, Kousho Wakae, Wen-Ping Jiang, Toshihide Hamabe-Horiike, Mariko Tanaka, Takumi Nishiuchi and 15 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Hirotomo DochiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0001-5711-7240
Satoru KondoDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0002-9066-0787
Takayuki MurataDepartment of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Masaki FukuyoDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Asuka NanboDepartment of Molecular and Cellular Virology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Sakamoto, Nagasaki, Japan.ORCID https://orcid.org/0000-0001-8764-1350
Kousho WakaeDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7767-6795
Wen-Ping JiangDepartment of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
Toshihide Hamabe-HoriikeCenter for Biochemical Research and Education, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0001-9075-9982
Mariko TanakaCenter for Biochemical Research and Education, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
Takumi NishiuchiDivision of Integrated Omics Research, Bioscience Core Facility, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Ishikawa, Japan.
Harue MizokamiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Makiko Moriyama-KitaDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Eiji KobayashiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Nobuyuki HiraiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Takeshi KomoriDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Takayoshi UenoDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Yosuke NakanishiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Miyako HatanoDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Kazuhira EndoDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Hisashi SugimotoDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Naohiro WakisakaDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Shin-Hun JuangSchool of Pharmacy, China Medical University, Taichung, Taiwan.
Masamichi MuramatsuDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-6980-5515
Tomokazu YoshizakiDivision of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0002-2420-5540
Kanazawa University · JPChiba University · JPNational Institute of Infectious Diseases · JPChia Nan University of Pharmacy and Science · TWChina Medical University · TWFujita Health University · JPNagasaki University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 16H05480Ministry of Education, Culture, Sports, Science and Technology 17H01590
6 · The paper itself

Abstract

Several epidemiological studies have suggested that Epstein-Barr virus (EBV) lytic infection is essential for the development of nasopharyngeal carcinoma (NPC), as the elevation of antibody titers against EBV lytic proteins is a common feature of NPC. Although ZEBRA protein is a key trigger for the initiation of lytic infection, whether its expression affects the prognosis and pathogenesis of NPC remains unclear. In this study, 64 NPC biopsy specimens were analyzed using immunohistochemistry. We found that ZEBRA was significantly associated with a worsening of progression-free survival in NPC (adjusted hazard ratio, 3.58; 95% confidence interval, 1.08-11.87; p = 0.037). Moreover, ZEBRA expression positively correlated with key endocrinological proteins, estrogen receptor α, and aromatase. The transcriptional level of ZEBRA is activated by estrogen in an estrogen receptor α-dependent manner, resulting in an increase in structural gene expression levels and extracellular virus DNA copy number in NPC cell lines, reminiscent of lytic infection. Interestingly, it did not suppress cellular proliferation or increase apoptosis, in contrast with cells treated with 12-O-tetradecanoylphorbol-13-acetate and sodium butyrate, indicating that viral production induced by estrogen is not a cell lytic phenomenon. Our results suggest that intratumoral estrogen overproduced by aromatase could induce ZEBRA expression and EBV reactivation, contributing to the progression of NPC.

Indexed as

Epstein-Barr Virus InfectionsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsTrans-ActivatorsAromataseEstrogen Receptor alphaEstrogensHerpesvirus 4, HumanHumansAromataseBZLF1 protein, Herpesvirus 4, HumanEstrogen Receptor alphaEstrogensTrans-ActivatorsBZLF1estrogenlytic infectionnasopharyngeal carcinomaZEBRA

Identifiers

PMID35633182
PMCPMC9357606
OpenAlexW4281748545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.